Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 15, 2005

Primary Completion Date

August 15, 2011

Study Completion Date

August 15, 2011

Conditions
Abscess, Intra-Abdominal
Interventions
DRUG

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam

Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.

Trial Locations (1)

30625

Medical School Hannover, Hanover

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Hannover Medical School

OTHER